Every 424B that YD Bio Ltd (YDES) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow YDES and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YDES filings page.
YD Bio Limited (YDES) filed a prospectus supplement tied to its Form F-1, covering a mixed registration: 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares registered for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of additional warrants. YD Bio’s ordinary shares trade on Nasdaq Global Market under symbol YDES, with a last reported price of $4.80 on August 28, 2026.
Attached unaudited results for the six months ended June 30, 2026 show revenue of $846,501 versus $204,007 a year earlier and a loss from operations of $3.23 million. A non-cash $9.85 million gain from the change in fair value of warrant liabilities produced net income of $6.70 million and improved total shareholders’ equity from a deficit of $(2.86) million to $4.47 million.
Cash and cash equivalents declined from $6.01 million to $2.66 million, with net cash used in operating activities of $2.82 million. Management states that recurring losses (excluding warrant fair value changes), negative operating cash flows and funding needs raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance of the interim financial statements.
YD Bio Limited updates its prospectus covering 11,436,270 ordinary shares issuable upon exercise of public warrants, 58,571,199 ordinary shares for resale by selling shareholders, and 3,136,056 ordinary shares issuable upon exercise of warrants.
The supplement incorporates a Form 6-K describing the launch of two chrono-nutrition nutraceutical products in Taiwan under a physician-partnership model, in collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. YD Bio’s ordinary shares trade on the Nasdaq Global Market under “YDES,” with a last reported price of $2.51 per share on August 10, 2026.
YD Bio Limited files a Prospectus Supplement registering 11,500,000 ordinary shares issuable upon exercise of public warrants, alongside disclosures for 59,136,934 ordinary shares by selling shareholders and 5,425,000 ordinary shares issuable upon exercise of warrants, to the Prospectus dated November 17, 2025.
The supplement incorporates a Form 6-K reporting that subsidiary YD Bio USA, Inc. entered a Master Strategic Alliance Agreement with YC Biotech Co., Ltd. on February 24, 2026
The filing also notes a reported last sale price of $8.42 per share on February 25, 2026 and attaches a press release describing the parties’ plan to build a "Taiwan-U.S. Dual-Core" regulatory platform with YD Bio USA as exclusive U.S. Agent for FDA-related submissions.
YD Bio Limited filed a prospectus supplement tied to its Form F-1, covering 11,500,000 ordinary shares issuable on exercise of public warrants, 59,136,934 ordinary shares offered by selling shareholders, and 5,425,000 ordinary shares issuable upon exercise of additional warrants. The supplement attaches a Form 6-K describing a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology (SSMC) through a new holding company for total consideration of NT$839,832,000 (approximately US$26.87 million) paid in a mix of cash and newly issued YD Bio shares. Large SSMC shareholders will receive YD Bio shares via share swap, while others can choose cash or shares, all subject to six‑month or one‑year lock‑ups. Closing depends on due diligence, SSMC’s restructuring and no material adverse change, with diligence targeted by March 20, 2026 and closing about 30 days later, after which YD Bio would indirectly own all of SSMC’s business and assets.
YD Bio Limited has filed a prospectus covering a mixed offering linked to its recent business combination with Breeze Holdings. The company is registering up to 11,500,000 Ordinary Shares issuable upon exercise of Public Warrants at an exercise price of $11.50 per share, and registering for resale 59,136,934 existing Ordinary Shares plus 5,425,000 Ordinary Shares issuable upon exercise of Private Warrants held by selling shareholders.
YD Bio will not sell shares directly in this offering and will not receive proceeds from shareholder resales. It would receive up to $132,250,000 from full cash exercise of the Public Warrants and up to $62,387,500 from full cash exercise of the Private Warrants, but the Warrants may expire unexercised. As of November 14, 2025, 70,521,359 Ordinary Shares were outstanding, rising to 87,437,359 if all registered Warrants are exercised. The shares trade on Nasdaq’s Global Market under the symbol YDES, and the prospectus highlights that investing in these securities involves a high degree of risk.